Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-05-22
2007-05-22
Balasubramanian, Venkataraman (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C546S197000, C546S198000, C546S200000, C546S201000, C544S092000, C544S283000, C514S230500, C514S230800, C514S266200, C514S320000
Reexamination Certificate
active
10729155
ABSTRACT:
The present invention relates to compounds of Formula (I)as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
REFERENCES:
patent: 5932737 (1999-08-01), Itoh et al.
patent: 6313097 (2001-11-01), Eberlein et al.
patent: 6344449 (2002-02-01), Rudolf et al.
patent: 6521609 (2003-02-01), Doods et al.
patent: 6552043 (2003-04-01), Patchett et al.
patent: 2001/0036946 (2001-11-01), Rudolf et al.
patent: 2003/0139417 (2003-07-01), Eberlein et al.
patent: 2003/0181462 (2003-09-01), Doods et al.
patent: 2003/0191068 (2003-10-01), Trunk et al.
patent: 2003/0212057 (2003-11-01), Rudolf et al.
patent: 2003/0236282 (2003-12-01), Humaus et al.
patent: 2004/0014679 (2004-01-01), Trunk et al.
patent: 2004/0063735 (2004-04-01), Chaturvedula et al.
patent: 2004/0076587 (2004-04-01), Kruss et al.
patent: 2004/0132716 (2004-07-01), Rudolf et al.
patent: 2004/0192729 (2004-09-01), Rudolf et al.
patent: 2004/0204397 (2004-10-01), Chaturvedula et al.
patent: 2004/0214819 (2004-10-01), Rudolf et al.
patent: 2004/0229861 (2004-11-01), Burgey et al.
patent: 2004/0248816 (2004-12-01), Doods et al.
patent: 2005/0032783 (2005-02-01), Doods et al.
patent: 2005/0065094 (2005-03-01), Davidai
patent: 2005/0153959 (2005-07-01), Lu et al.
patent: 2005/0215546 (2005-09-01), Hurnaus et al.
patent: 2005/0215576 (2005-09-01), Degnan et al.
patent: 2005/0227968 (2005-10-01), Lustenberger et al.
patent: 2005/0233980 (2005-10-01), Doods et al.
patent: 2005/0234054 (2005-10-01), Mueller et al.
patent: 2005/0234067 (2005-10-01), Mueller et al.
patent: 2005/0250763 (2005-11-01), Mueller et al.
patent: 2005/0256098 (2005-11-01), Burgey et al.
patent: 2005/0256099 (2005-11-01), Mueller et al.
patent: 2005/0272955 (2005-12-01), Zimmer et al.
patent: 2 387 613 (2001-05-01), None
patent: 2 503 455 (2005-04-01), None
patent: 1 227 090 (2002-07-01), None
patent: WO 97/09046 (1997-03-01), None
patent: WO 98/09630 (1998-03-01), None
patent: WO 98/11128 (1998-03-01), None
patent: WO 98/56779 (1998-12-01), None
patent: WO 99/52875 (1999-10-01), None
patent: WO 00/18764 (2000-04-01), None
patent: WO 00/55154 (2000-09-01), None
patent: WO 01/25228 (2001-04-01), None
patent: WO 01/32648 (2001-05-01), None
patent: WO 01/32649 (2001-05-01), None
patent: WO 01/49676 (2001-07-01), None
patent: WO 02/10140 (2002-02-01), None
patent: WO 03/027252 (2003-04-01), None
patent: WO 03/070753 (2003-08-01), None
patent: WO 03/076432 (2003-09-01), None
patent: WO 03/104236 (2003-12-01), None
patent: WO 2004/037810 (2004-05-01), None
patent: WO 2004/082602 (2004-09-01), None
patent: WO 2004/082605 (2004-09-01), None
patent: WO 2004/082678 (2004-09-01), None
patent: WO 2004/083187 (2004-09-01), None
patent: WO 2004/087649 (2004-10-01), None
patent: WO 2004/091514 (2004-10-01), None
patent: WO 2004/092166 (2004-10-01), None
patent: WO 2004/092166 (2004-10-01), None
patent: WO 2004/092168 (2004-10-01), None
patent: WO 2004/092168 (2004-10-01), None
patent: WO 2005/000807 (2005-01-01), None
patent: WO 2005/009962 (2005-02-01), None
patent: WO 2005/013894 (2005-02-01), None
patent: WO 2005/056550 (2005-06-01), None
patent: WO 2005/065779 (2005-07-01), None
patent: WO 2005/072308 (2005-08-01), None
patent: WO2005/084672 (2005-09-01), None
patent: WO 2005/092880 (2005-10-01), None
patent: WO 2005/095383 (2005-10-01), None
patent: WO 2005/100343 (2005-10-01), None
patent: WO 2005/100352 (2005-10-01), None
patent: WO/2005/100360 (2005-10-01), None
patent: WO 2005/102322 (2005-11-01), None
patent: WO 2005/103037 (2005-11-01), None
patent: WO 2005/121078 (2005-12-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Vippagunta et al., Advanced Drug Delivery Reviews 48: 3-26, 2001.
U.S. Appl. No 11/247,697, Chaturvedula et al., filed Oct. 11, 2005.
U.S. Appl. No. 11/291,670, Chaturvedula et al., filed Dec. 1, 2005.
Carlström, A.-S. and Frejd, T., Palladium-Catalyzed Synthesis of Didehydroamino Acid Derivatives,Synthesis, 1989, 6, 414-418.
Carlström, A.-S. and Frejd, T., “Palladium-Catalyzed Bis-coupling of Dihaloaromatics with 2-Amidoacrylates”,J. Org. Chem., 1991, 56, 1289-1293.
Dygos, J.H., et al., “A Convenient Asymmetric Synthesis of the Unnatural Amino Acid 2,6-Dimethyl-L-tyrosine”,Synthesis, 1992, 741-743.
Rudolf, K., et al., “Development of Human Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists. 1. Potent and Selective Small Molecule CGRP Antagonists. 1-[N2-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl] L-lysyl]-4-(4-pyridinyl)piperazine: The First CGRP Antagonist for Clincal Trials in Acute Migraine”,J. Med. Chem.2005, 48, 5921-5931.
Xin, Z., et al., “Potent, Selective Inhibitors of Protein Tyrosine Phosphatase IB”,Bioorg.&Med. Chem. Lett., 2003, 13, 1887-1890.
Hall, et al., “Interaction of human adrenomedullin 13-52 with calcitonin gene-related peptide receptors in the microvasculature of the rat and hamster,”British Journal of Pharmacology, 1995, 114, 592-597.
Hall, et al., “Interaction of amylin with calcitonin gene-related peptide receptors in the microvasculature of the hamster cheek pouch in vivo,”British Journal of Pharmacology, 1999, 126, 280-284.
Doods, et al., “Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist,”British Journal of Pharmacology, 2000, 129, 420-423.
Chu, et al., “The calcitonin gene-related peptide (CGRP) antagonist CGRP8-37 blocks vasodilatation in inflammed rat skin: involvement of adrenomedullin in addition to CGRP,”Neuroscience Letters, 310, 2001, 169-172.
Williamson, et al., “Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat-intravital microscope studies,”Cephalalgia, 1997, 17, 525-31.
Escott, et al., “Effect of a calcitonin gene-related peptide antagonist (CGRP8-37) on skin vasodilatation and oedema induced by stimulation of the rat saphenous nerve,”British Journal of Pharmacology, 1993, 110, 772-776.
Escott, et al., “Trigeminal ganglion stimulation increases facial skin blood flow in the rat: a major role for calcitonin gene-related peptide,”Brain Research, 669, 1995, 93-99.
Williamson, et al., “Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat,”Cephalalgia, 1997, 17, 518-524.
De Vries, et al., “Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy,”European Journal of Pharmacology, 375, 1999, 61-74.
Shen, et al., “Functional role of α-calcitonin gene-related peptide in the regulation of the cardiovascular system,”Journal of Pharmacology and Experimental Therapeutics, 2001, 298, 2, 551-558.
Lassen, et al., “CGRP may play a causative role in migraine,”Cephalalgia, 2002, 22, 54-61.
Ashina, et al., “Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks,”Pain, 86, 2000, 133-138.
Gallai, et al., “Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally,”Cephalalgia, 1995, 15, 384-390.
Goadsby, et al., “Vasoactive peptide release in the extracerebral circulation of humans during migraine headache,”Annals of Neurology, 1990, 28, 2, 183-187.
Grant, et al., “Evidence of a role
Chaturvedula Prasad V.
Chen Ling
Civiello Rita
Degnan Andrew P.
Dubowchik Gene M.
Balasubramanian Venkataraman
Bristol--Myers Squibb Company
Makujina Shah R.
LandOfFree
Calcitonin gene related peptide receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Calcitonin gene related peptide receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Calcitonin gene related peptide receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3775595